RT Conference Proceedings
T1 Nivolumab (NIVO) plus ipilimumab (IPI) as first-line (1L) treatment (tx) for patients (pts) with advanced NSCLC (aNSCLC) and baseline (BL) brain metastases (mets): Intracranial and systemic outcomes from CheckMate 227 Part 1
A1 Reck, M.
A1 Ciuleanu, T. E.
A1 Pluzanski, A.
A1 Lee, J. S.
A1 Caro, R. Bernabe
A1 Linardou, H.
A1 Burgers, J.
A1 Gallardo, C.
A1 Nishio, M.
A1 Peters, S.
A1 Paz-Ares, L. G.
A1 Hellmann, M. D.
A1 Borghaei, H.
A1 Ramalingam, S. S.
A1 O'Byrne, K.
A1 Hu, N.
A1 Bushong, J.
A1 Eccles, L.
A1 Grootendorst, D.
A1 Brahmer, J. R.
PB Elsevier
SN 0923-7534
YR 2021
FD 2021-12-10
LK https://hdl.handle.net/10668/27921
UL https://hdl.handle.net/10668/27921
LA en
DS RISalud
RD Apr 12, 2025